Targeting up to 30 "tumor neoantigens" innovative T cell therapy takes a critical step

Today, Genocea Biosciences announced that its research peripheral T cell therapy GEN-011 has completed its first patient administration in a phase 1/2a clinical trial

The research and development strategy of using the T cells of the immune system to kill tumors has produced a variety of CAR-T cells, and a number of TCR cell therapies are also in the development process

Genocea's unique technology platform is called ATLAS

▲Introduction to the ATLAS platform (picture source: Genocea's official website)

Then, using neoantigens that can activate T cells, activate and expand the T cells obtained from the patient's blood so that they have the ability to recognize neoantigens

▲The production process of GEN-011 (picture source: Genocea official website)

Note: The original text has been deleted

Reference materials:

[1] Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy.

[2] Genocea.